Meropenem is a penem antibacterial carbapenem antibiotic used intravenously for serious bacterial infections including complicated skin/skin-structure infections, intra-abdominal infections, and bacterial meningitis in pediatric populations. It is marketed under the brand Merrem IV. Initial U.S. approval was in 1996.
BioVersys AG received FDA approval to enroll U.S. patients in a global Phase 3 trial evaluating BV100 for hospital-acquired pneumonia caused by carbapenem-resistant Acinetobacter baumannii, with trial completion expected by end of 2027.
The CDC is investigating a multistate outbreak of extensively drug-resistant Salmonella Newport with an NDM-1 gene linked to Rosabella moringa powder capsules, marking the first documented outbreak of Salmonella with an NDM-1 gene in the United States.
CDC and FDA are investigating a multistate outbreak of extensively drug-resistant Salmonella Newport infections linked to Rosabella brand moringa powder capsules, with seven people sickened across seven states and three requiring hospitalization.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07556107 |
The Vancomycin Piperacillin/Tazobactam (VPT) Patient Safety Trial (VPS) |
NOT_YET_RECRUITING | PHASE4 |
| NCT07445282 |
This Randomized Controlled Trial Evaluates the Comparative Efficacy of Intravenous Meropenem Alone Versus Intravenous Meropenem Combined With Oral Azithromycin in Children Aged 6 Months to Under 5 Years Diagnosed With Blood Culture-confirmed Extensively Drug-resistant Uncomplicated Typhoid Fever |
COMPLETED | PHASE4 |
| NCT06916156 |
Evaluation of the Concentration of ANT3310 and Meropenem in the Lung in Healthy Adult Participants |
COMPLETED | PHASE1 |
| NCT06841731 |
A Trial of HRS-8427 in the Treatment of Adults With Bacterial Pneumonia |
RECRUITING | PHASE2 |
| NCT06527677 |
Assessment of the Pharmacokinetics and Safety of ANT3310 Combined With Meropenem in Renally Impaired Subjects |
COMPLETED | PHASE1 |
| NCT06342115 |
Ceftolozane/Tazobactam Versus Meropenem for Febrile Neutropenia on Patients Colonized With or at Risk for Infection With Extended Spectrum Beta Lactamase - Producing Pathogens |
RECRUITING | PHASE4 |
| NCT06184659 |
Empirical Meropenem Versus Piperacillin/Tazobactam for Adult Patients With Sepsis |
RECRUITING | PHASE4 |
| NCT06168734 |
Cefepime-taniborbactam vs Meropenem in Adults With VABP or Ventilated HABP |
WITHDRAWN | PHASE3 |
| NCT06072248 |
Effect of Bronchoscopy on the Outcome of Patients With Severe Sepsis With ARDS and Complicated by VAP From Prolonged Ventilation |
COMPLETED | PHASE1/PHASE2 |
| NCT06072222 |
Effect of Bronchoscopy on the Outcome of Patients With Severe Sepsis With ARDS and Complicated by VAP From Prolonged Ventilation |
COMPLETED | PHASE1/PHASE2 |
